These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29212173)

  • 1. Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer.
    Shimada Y; Kameyama H; Nagahashi M; Ichikawa H; Muneoka Y; Yagi R; Tajima Y; Okamura T; Nakano M; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Hayashida T; Takaishi H; Kitagawa Y; Oki E; Konishi T; Ishida F; Kudo SE; Ring JE; Protopopov A; Lyle S; Ling Y; Okuda S; Ishikawa T; Akazawa K; Takabe K; Wakai T
    Oncotarget; 2017 Nov; 8(55):93567-93579. PubMed ID: 29212173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
    Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T
    Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in T cell immune-related lncRNA and mRNA expression patterns between right- and left-sided colorectal cancers.
    Lijuan Y; Yinhang W; Yangyanqiu W; Xiaohui H; Yunhai W; Shuwen H
    Hum Immunol; 2021 Dec; 82(12):950-959. PubMed ID: 34426030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and prognostic differences between surgically resected right-sided and left-sided colorectal cancer.
    Fukata K; Yuasa N; Takeuchi E; Miyake H; Nagai H; Yoshioka Y; Miyata K
    Surg Today; 2020 Mar; 50(3):267-274. PubMed ID: 31612331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intertwined leukocyte balances in tumours and peripheral blood as robust predictors of right and left colorectal cancer survival.
    Cantero-Cid R; Montalbán-Hernández KM; Guevara J; Pascual-Iglesias A; Pulido E; Casalvilla JC; Marcano C; Serrano CB; Valentín J; Bonel-Pérez GC; Avendaño-Ortiz J; Terrón V; Lozano-Rodríguez R; Martín-Quirós A; Marín E; Pena E; Guerra-Pastrián L; López-Collazo E; Aguirre LA
    World J Gastrointest Oncol; 2022 Jan; 14(1):295-318. PubMed ID: 35116118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
    BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and Predictive Models for Left- and Right- Colorectal Cancer Patients: A Bioinformatics Analysis Based on Ferroptosis-Related Genes.
    Chen Y; Li H
    Front Oncol; 2022; 12():833834. PubMed ID: 35265525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative Hyperselection of Patients With
    Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature.
    Baran B; Mert Ozupek N; Yerli Tetik N; Acar E; Bekcioglu O; Baskin Y
    Gastroenterology Res; 2018 Aug; 11(4):264-273. PubMed ID: 30116425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
    Moretto R; Cremolini C; Rossini D; Pietrantonio F; Battaglin F; Mennitto A; Bergamo F; Loupakis F; Marmorino F; Berenato R; Marsico VA; Caporale M; Antoniotti C; Masi G; Salvatore L; Borelli B; Fontanini G; Lonardi S; De Braud F; Falcone A
    Oncologist; 2016 Aug; 21(8):988-94. PubMed ID: 27382031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative Ultraselection of Patients With
    Randon G; Maddalena G; Germani MM; Pircher CC; Manca P; Bergamo F; Giordano M; Sposetti C; Montagna A; Vetere G; Zambelli L; Rasola C; Boccaccino A; Pagani F; Ambrosini M; Massafra M; Fontanini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    JCO Precis Oncol; 2022 Apr; 6():e2200037. PubMed ID: 35544729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
    Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
    BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients.
    Natsume S; Yamaguchi T; Takao M; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Nakano D; Horiguchi SI; Koizumi K; Miyaki M
    Jpn J Clin Oncol; 2018 Jul; 48(7):609-618. PubMed ID: 29767751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.
    Archwamety A; Teeyapun N; Siripoon T; Poungvarin N; Tanasanvimon S; Sirachainan E; Akewanlop C; Korphaisarn K
    Front Oncol; 2022; 12():813009. PubMed ID: 35242708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
    Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
    Cremolini C; Morano F; Moretto R; Berenato R; Tamborini E; Perrone F; Rossini D; Gloghini A; Busico A; Zucchelli G; Baratelli C; Tamburini E; Tampellini M; Sensi E; Fucà G; Volpi C; Milione M; Di Maio M; Fontanini G; De Braud F; Falcone A; Pietrantonio F
    Ann Oncol; 2017 Dec; 28(12):3009-3014. PubMed ID: 29045518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and molecular differences in colorectal cancer according to location.
    Hsu YL; Lin CC; Jiang JK; Lin HH; Lan YT; Wang HS; Yang SH; Chen WS; Lin TC; Lin JK; Lin PC; Chang SC
    Int J Biol Markers; 2019 Mar; 34(1):47-53. PubMed ID: 30854932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.